In May 2022, Idorsia announces that PRECISION, our Phase 3 study of aprocitentan in patients with resistant hypertension, has met both the primary and secondary endpoints.

• Investor webcast
• Read the media release

Idorsia published its full year financial results 2021 on Tuesday
February 8, 2022.

• Investor webcast
• Investor webcast presentation

In January 2022, Idorsia announced the publication of "Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials" in The Lancet Neurology.

• Webcast
• Read the media release
• Investor presentation

Jean-Paul Clozel, Chief Executive Officer of Idorsia, presented at the 40^th J.P. Morgan Healthcare Conference on January 12, 2022. The conference took place virtually.

• Webcast
• Read the media release
• Investor presentation

Idorsia published its half year financial results 2021 on Tuesday
July 27, 2021.

• Investor webcast
• Investor webcast presentation

In June 2021, Idorsia announced the initiation of the Phase 3 registration study “SOS-AMI” to evaluate the efficacy and safety of self-administered subcutaneous selatogrel, Idorsia’s P2Y₁₂ receptor antagonist, in suspected acute myocardial infarction (AMI).

• Investor webcast
• Investor webcast presentation

Idorsia published its full year financial results 2020 on Thursday February 4, 2021.

• Investor webcast presentation

On August 28, 2020, the positive results from the first pivotal Phase 3 study (evaluating 25 and 50 mg doses) of our investigational dual orexin receptor antagonist, daridorexant, in adult and elderly patients with insomnia, were presented by Dr Thomas Roth at SLEEP 2020.

The Associated Professional Sleep Societies (APSS) event, SLEEP 2020, is the world’s largest meeting devoted entirely to clinical sleep medicine, and sleep and circadian research.

• SLEEP 2020
• Presentation
• Press Release
• Late breaker abstract

Idorsia published its half year financial results 2020 on Thursday July 23, 2020.

• Webcast presentation

Idorsia published its full year financial results 2019 on Thursday February 6, 2020.

• Investor webcast presentation

Idorsia published its half year financial results 2019 on Tuesday July 23, 2019.

• Investor webcast presentation

Idorsia published its full year financial results 2018 on Thursday February 7, 2019.

• Investor webcast presentation

In June 2018, Idorsia announced that the first patient had been enrolled into PRECISION, a Phase 3 study to investigate the efficacy and safety of aprocitentan for resistant hypertension management in adults.

• Investor webcast
• Investor webcast presentation

In June 2018, Idorsia announced that it is initiating a Phase 3 study, REACT, to investigate the efficacy and safety of clazosentan for the prevention of clinical deterioration due to vasospasm-related delayed cerebral ischemia in patients following an aneurysmal subarachnoid hemorrhage. The company also gave an update on the Japanese registration program and the establishment of Idorsia Pharmaceuticals Japan.

• Investor webcast
• Investor webcast presentation

The information in these investor webcasts was factually accurate at the time of broadcast. These webcasts remain on the Idorsia website for historical purposes only. Idorsia assumes no responsibility to update the information to reflect subsequent developments. Readers should not rely upon the information in these presentations as current or accurate after their publication dates.